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Abstract
Background Increasing evidence indicates that alterations to the function and subunit composition of the
glutamatergic NMDA receptor are associated with the pathophysiology of schizophrenia. The GluN2B
protein is a structural and functional subunit of the NMDA receptor, with a growing body of evidence
indicating it plays a critical role in cognitive functions mediated by the NMDA receptor. The hippocampus
plays a key role in cognitive function, with studies suggesting lateralised glutamatergic dysfunction in this
region may contribute to the cognitive deficits observed in schizophrenia patients. The present study, for the
first time, investigated GluN2B protein and binding density in the left and right hippocampus of 20
schizophrenia subjects compared to 20 matched controls. Methods The dentate gyrus of 20 schizophrenia and
20 control subjects, matched for age, post-mortem interval, and pH, was obtained from the NSW Tissue
Resource Centre, Australia. Each group consisted of dentate gyrus from the left hemisphere (n = 10) and right
hemisphere (n = 10). GluN2B protein density was measured via immunoblotting. GluN2B binding density
was measured using the GluN2B antagonist, [3H] Ifenprodil. Analyses of covariance, covarying for
demographic variables that influenced the data, were used to test for statistical significance between
schizophrenia and control groups. Pearson's correlations were used to determine the association of GluN2B
protein and binding density with demographic and clinical variables, including lifetime antipsychotic drug
exposure. Results GluN2B protein levels were decreased by 43% in the left hemisphere of schizophrenia
subjects compared to controls (p = 0.012). There was no difference in GluN2B protein levels in the right
hemisphere of schizophrenia subjects compared to controls. There were no differences in [3H] Ifenprodil
binding according to diagnosis or hemisphere. There were no associations between GluN2B measures and
lifetime antipsychotic drug exposure. Conclusions Our findings provide the first evidence of GluN2 protein
abnormalities in the hippocampus in schizophrenia, highlighting the hippocampal lateralisation in this
disorder. We suggest this deficit could contribute to the cognitive dysfunctions that arise in patients. These
findings provide preliminary support for the development of therapeutics that target the GluN2B subunit, as a
novel therapy for schizophrenia, especially the cognitive dysfunctions.
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Abstract
Background: Increasing evidence indicates that alterations to the function and subunit composition of the
glutamatergic NMDA receptor are associated with the pathophysiology of schizophrenia. The GluN2B protein is a
structural and functional subunit of the NMDA receptor, with a growing body of evidence indicating it plays a
critical role in cognitive functions mediated by the NMDA receptor. The hippocampus plays a key role in cognitive
function, with studies suggesting lateralised glutamatergic dysfunction in this region may contribute to the cognitive
deficits observed in schizophrenia patients. The present study, for the first time, investigated GluN2B protein and
binding density in the left and right hippocampus of 20 schizophrenia subjects compared to 20 matched controls.
Methods: The dentate gyrus of 20 schizophrenia and 20 control subjects, matched for age, post-mortem interval, and
pH, was obtained from the NSW Tissue Resource Centre, Australia. Each group consisted of dentate gyrus from the left
hemisphere (n = 10) and right hemisphere (n = 10). GluN2B protein density was measured via immunoblotting. GluN2B
binding density was measured using the GluN2B antagonist, [3H] Ifenprodil. Analyses of covariance, covarying for
demographic variables that influenced the data, were used to test for statistical significance between schizophrenia
and control groups. Pearson’s correlations were used to determine the association of GluN2B protein and binding
density with demographic and clinical variables, including lifetime antipsychotic drug exposure.
Results: GluN2B protein levels were decreased by 43% in the left hemisphere of schizophrenia subjects compared to
controls (p = 0.012). There was no difference in GluN2B protein levels in the right hemisphere of schizophrenia subjects
compared to controls. There were no differences in [3H] Ifenprodil binding according to diagnosis or hemisphere.
There were no associations between GluN2B measures and lifetime antipsychotic drug exposure.
Conclusions: Our findings provide the first evidence of GluN2 protein abnormalities in the hippocampus in
schizophrenia, highlighting the hippocampal lateralisation in this disorder. We suggest this deficit could contribute to
the cognitive dysfunctions that arise in patients. These findings provide preliminary support for the development of
therapeutics that target the GluN2B subunit, as a novel therapy for schizophrenia, especially the cognitive dysfunctions.
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Background
The hippocampus plays an important role in learning
and memory, cognitive functions that are disrupted in
schizophrenia [1]. Several lines of research have shown
that there are various structural and functional abnor-
malities in the hippocampus of schizophrenia patients,
including a reduction in hippocampal volume, altered
synaptic connections (evidenced through reductions in
synaptosomal proteins such as synaptophysin, SNAP-25
and synapsin) and changes in neurotransmitter receptors,
implicating the hippocampus in the pathophysiology of
schizophrenia [2].
Dysregulation of glutamatergic neurotransmission, par-
ticularly associated with the N-methyl-D-aspartate glu-
tamate receptor (NMDAR) is also widely believed to play
a central role in schizophrenia pathophysiology [3-5]. The
NMDAR is assembled in various subunit combinations,
with obligatory GluN1 subunits coupled primarily with
GluN2A, B, C, or D subunits [6]. Various studies have
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found alterations in NMDAR binding and GluN1 subunit
mRNA and protein in the hippocampus of schizophrenia
subjects (For review see [3]). Some replicated findings in-
clude a decrease in GluN1 mRNA in the dentate gyrus of
schizophrenia patients [7,8], a decrease or no change in
NMDAR binding density [7,9,10] and most interestingly a
more pronounced decrease in NMDAR binding and
GluN1 mRNA and protein in the left hippocampus of
schizophrenia subjects compared to the right [8,9,11].
These studies suggest a lateralised glutamatergic dysregu-
lation in the hippocampus of schizophrenia subjects [2].
With regards to the GluN2 subunits, one study has re-
ported an increase in GluN2B mRNA in the hippocampus
in schizophrenia, with two further studies reporting no
change, and no changes have been reported for GluN2A
mRNA, or the less expressed 2C and 2D subunits
[7,10,12]. The status of GluN2 proteins in the hippo-
campus in schizophrenia is currently unknown, however
one study did report no change in [3H] ifenprodil bind-
ing to GluN2B in the hippocampus of schizophrenia
subjects [10]. These aforementioned studies, however,
did not report hemisphere specific analyses which is an
important aspect to consider in studies of the hippo-
campus [2].
The GluN2 subunit composition defines the functional
properties of the NMDAR [3], therefore to understand
the NMDAR dysregulation in schizophrenia it is critical
to investigate alterations to the GluN2 subunits. GluN2A
and GluN2B are the principle subunits in the hippocam-
pus [13]; evidence suggests that the GluN2B subunit in
the hippocampus is particularly important for NMDAR
channel function [14], long-term potentiation (LTP) and
associated cognitive functions such as spatial learning
[15]. Accordingly, specifically targeting the GluN2B sub-
unit has been suggested as a novel mechanism to treat
cognitive dysfunction in schizophrenia patients and other
cognitive disorders [16,17].
The aim of this study was to determine whether there
are alterations in GluN2B subunit density in the hippo-
campus of schizophrenia subjects compared to controls
and whether any effects were hemisphere specific. We
used immunoblot to detect GluN2B protein density and
[3H] ifenprodil, which binds to the polyamine site of the
GluN2B subunit, to assess GluN2B binding density.
Methods
Brain Tissue
Post-mortem human brain tissue was acquired from the
NSW Tissue Resource Centre at the University of Sydney.
The cohorts consisted of schizophrenia patients, with the
diagnosis of schizophrenia confirmed according to DSM-
IV and healthy controls, with no known history of psychi-
atric illness (Table 1). The cohort for the western blotting
consisted of 20 schizophrenia and 20 control subjects; the
cohort for receptor binding consisted of 20 schizophrenia
and 21 control subjects. There was an overlap of 84% (37/
44) between subjects included in the western blot and
receptor binding studies. There were no significant differ-
ences in age, brain pH, post-mortem interval (PMI) or
brain weight between the schizophrenia and control sub-
jects included in the protein or binding studies. This study
was approved by the University of Wollongong Human
Research Ethics Committee (HE99/222).
Immunoblot
Immunoblotting was performed as previously described
[18]. Tissue from the dentate gyrus of the hippocampus
was homogenised in 0.1 M TrisHCl containing 10 μl/ml
protease inhibitor cocktail (Sigma-Aldrich), 0.625 μl/ml
aprotinin and 0.5 μl/ml glycerol. GluN2B protein density
was measured using an anti-GluN2B antibody (#MAB5778,
1/625; Millipore) diluted in PBS-Tcontaining 1% skim milk.
A mouse anti-actin antibody was used as an internal stand-
ard (#MAB1501, 1/100 000; Millipore). Samples were run
in triplicate at a concentration of 10 μg of total protein.
GluN2B protein bands were detected on Kodak BioMax
MR Film (Sigma-Aldrich) using enhanced chemiliumines-
cence reagents (GE Healthcare). Films were analysed using
Quantity One software (BioRad); the optical density of each
band was normalised to the respective β-actin band and av-
eraged over the three runs.
In situ radioligand binding
[3H] Ifenprodil binding was performed based on the
method described previously [19]. Three slides per sub-
ject, each containing 14 μm hippocampal sections, were
incubated for 3 hours at 4°C in 0.05 M TrisHCl (pH 7.4)
with 20nM [3H] Ifenprodil (GluN2B antagonist: specific
activity 40 Ci/mmol; PerkinElmer). Due to previous
findings that [3H] ifenprodil has some affinity for sigma
receptors, piperazine acceptor sites, and non-GluN2B
polyamine sites [20-22], the following pharmacological
inhibitors were included in the incubation assay: 3 μM
R(+)-3-(3-hydroxyphenyl)-N-propylpiperidine hydrochlor-
ide (+3PPP; to block non-specific binding to the sigma re-
ceptor), 30 μM GBR-12909 (to block piperazine sites) and
1 mM trifluoperazine (to block low affinity polyamine sen-
sitive sites on adrenergic, dopaminergic and cholinergic
receptors). Adjacent sections were incubated in the
same solution, with the addition of 20 μM Ifenprodil
(Sigma-Aldrich) to determine any non-specific binding.
All sections were washed in 0.05 M TrisHCl (pH 7.4)
for 3x5 minutes at 4°C, rinsed in distilled water and air-
dried. All slides were exposed to Kodak BioMax MR
Film (Sigma-Aldrich) for 16 weeks. Films were analysed
using Quantity One software; quantification was per-
formed by taking the average optical density from the den-
tate gyrus in three slides. Specific binding was determined
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by subtracting non-specific binding density from total
binding density.
Statistical Analyses
The data were checked for triplicate (standard deviation >
30% mean) and population outliers (using box-plots) and
Kolmogorov-Smirnov tests were used to confirm data nor-
mality. T-tests, ANOVAs and ANCOVAs with LSD post-
hoc were used to determine the effects of diagnosis overall
and within the left and right hemispheres, co-varying
for variables that were shown to correlate with the data.
Pearson’s correlations were used to determine relation-
ships to continuous variables including age at death,
PMI, pH, brain weight, antipsychotic medication, age of
illness onset, and duration of illness.
Results
Left hippocampal deficits in GluN2B subunit protein in
schizophrenia subjects
While we observed no overall difference in GluN2B pro-
tein density in the dentate gyrus of schizophrenia subjects
compared to controls (t36 = 1.452, p = 0.155), we found a
significant difference between hemisphere-specific sub-
groups (F3,34 = 2.882, p = 0.050), with a 43% reduction in
GluN2B protein in the left hippocampus of schizophrenia
subjects compared to the left hippocampus of controls
(p = 0.012) and a 40% reduction in GluN2B protein in
the left hippocampus of schizophrenia subjects compared
to the right hippocampus from schizophrenia subjects
(p = 0.023) (Figure 1a and 1b). GluN2B protein density
correlated significantly with brain pH (r = −0.386, p = 0.017)
and there was a trend for a correlation with PMI
(r = −0.318, p = 0.051) in the whole cohort (Table 2). Similar
correlations were observed in the control subjects (pH:
r = −0.662, p = 0.002; PMI: r = −0.483, p = 0.036) but not
the schizophrenia subjects (pH: r = 0.162, p = 0.506; PMI:
r = −0.116, p = 0.636). ANCOVAs correcting for brain pH
and PMI confirmed that there was no overall difference in
GluN2B protein density between schizophrenia and control
subjects (F1,34 = 2.004, p = 0.166) and that there was a sig-
nificant effect between the 4 hemisphere-specific subgroups
(F3,32 = 3.824, p = 0.019). Importantly, there was no correl-
ation between GluN2B protein density in the schizophrenia
subjects and length of illness, age of disease onset or esti-
mated daily antipsychotic medication dose (Table 2).
No change in GluN2B binding density in schizophrenia
subjects compared to controls
There was no overall difference in [3H] Ifenprodil bind-
ing in the dentate gyrus between schizophrenia and
Table 1 Cohort demographic and clinical characteristics
Variable Cohort Control Schizophrenia t p
n Western Blot 20 20
Receptor binding 21 20
Age at death Western Blot 54.5 ± 13.4 (24-73) 54.7 ± 12.8 (27-75) -0.036 0.971
Mean years ± SD (range) Receptor binding 55.3 ± 13.1 (24-73) 54.8 ± 12.8 (27-75) 0.132 0.895
Post-mortem interval Western Blot 28.2 ± 13.3 29.5 ± 12.5 -0.307 0.761
Mean hours ± SD Receptor binding 30.5 ± 13.6 28.9 ± 12.3 0.388 0.700
pH Western Blot 6.47 ± 0.35 6.47 ± 0.16 0.069 0.945
Mean ± SD Receptor binding 6.44 ± 0.35 6.47 ± 0.16 -0.381 0.706
Gender Western Blot 12 M/8 F 12 M/8 F N/A N/A
Receptor binding 12 M/9 F 12 M/8 F N/A N/A
Hemisphere Western Blot 10 L/10R 11 L/9R N/A N/A
Receptor binding 10 L/11R 10 L/10R N/A N/A
Brain weight Western Blot 1410 ± 128 1358 ± 172 1.085 0.285
Mean grams ± SD Receptor binding 1396 ± 139 1358 ± 172 0.792 0.433
Estimated daily antipsychotic drug dose Western Blot N/A 782 ± 543 N/A N/A
Mean CPZ equiv ± SD Receptor binding N/A 809 ± 529 N/A N/A
Age of onset Western Blot N/A 24.1 ± 8.2 (14-44) N/A N/A
Mean years ± SD (range) Receptor binding N/A 23.6 ± 8.1 (14-44) N/A N/A
Duration of illness Western Blot N/A 30.6 ± 11.9 (12-47) N/A N/A
Mean years ± SD (range) Receptor binding N/A 30.7 ± 11.9 (12-47) N/A N/A
There was an overlap of 84% (37/44) between subjects included in the western blot and receptor binding studies. Independent t-tests show no significant
differences in age at death, post-mortem interval, pH or brain weight between schizophrenia and control groups; Abbreviations: M, male; F, female; L, left; R, right;
PMI, post-mortem interval; CPZ equiv, chlorpromazine equivalents. N/A, not applicable.
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control subjects (t39 = 0.808, p = 0.424) and no hemisphere
dependent effects (F3,37 = 0.394, p = 0.758) (Figure 1c). [
3H]
Ifenprodil binding density correlated with age at death in
the whole cohort (r = −0.309, p = 0.049), showed a trend
towards a correlation in control subjects (r = −0.408,
p = 0.067), but did not correlate in schizophrenia subjects
(r = −0.212, p = 0.369) (Table 2). ANCOVAs to correct for
age at death confirmed no difference in [3H] Ifenprodil
binding density between schizophrenia and control sub-
jects (F1,38 = 0.780, p = 0.383) or hemisphere-specific sub-
groups (F3,36 = 0.472, p = 0.704). There was no correlation
between GluN2B binding density in the schizophrenia sub-
jects and length of illness, age of disease onset or estimated
daily antipsychotic medication dose (Table 2).
Discussion
In the present study we have identified a large (43%) re-
duction in GluN2B protein levels in the hippocampal
dentate gyrus in schizophrenia. This reduction was specific
to the left hemisphere, highlighting the hippocampal lat-
eralisation in the pathophysiology of schizophrenia. In
addition, we have confirmed previous results, this time in a
larger cohort (n = 15 cf. n = 20), indicating no change in
[3H] ifenprodil binding to GluN2B in the hippocampus of
schizophrenia subjects in comparison to controls [10] and
extended these findings to report no hemisphere specific
alteration in GluN2B binding density.
It is well documented that the hippocampus is altered in
schizophrenia and there is evidence to suggest that the left
hemisphere shows more pronounced deficits in NMDAR
expression than the right hemisphere. Previous studies
have reported a more pronounced decrease in GluN1
mRNA and protein in the left hemisphere of schizophrenia
subjects [8,11] as well as a reduction in [123I] CNS-1261
binding to the NMDAR channel in the left hippocampus
of medication free schizophrenia subjects [9]. Ours is the
first study in the hippocampus to report such a lateralisa-
tion effect with any of the GluN2 subunits, however, to our
knowledge, the protein density of the other GluN2 sub-
units has not yet been investigated in this region. It has
previously been reported that deletion of the GluN1 sub-
unit in the CA1 region of the hippocampus results in re-
duced expression of the GluN2B subunit in the dendrites
of pyramidal neurons in mice [23], suggesting our finding
of reduced GluN2B in the hippocampus could be associ-
ated with the reductions in GluN1 previously reported in
the left hippocampus in schizophrenia.
While we found a reduction in GluN2B protein levels
in the present study, this was accompanied by no change
in GluN2B binding density. [3H] Ifenprodil binds to the
polyamine site on GluN2B subunits. While ifenprodil does
also have some affinity for sigma, piperazine, adrenergic
receptors and other polyamine sites [20-22], pharmaco-
logical inhibitors were used to block these sites in the
Figure 1 GluN2B protein and binding density in the
hippocampus (dentate gyrus) of schizophrenia and control
subjects. a. GluN2B protein density, normalised to β-actin, in the left
and right hemisphere of schizophrenia (SZ) and control (CT) subjects.
GluN2B was reduced in the left hemisphere of subjects with
schizophrenia, compared to the left hemisphere of controls (−43%,
p = 0.012) and compared to the right hemisphere of schizophrenia
subjects (−40%, p = 0.023 ). *:p < 0.05. b. Representative blot
showing GluN2B and β-actin protein expression in control (CT) and
schizophrenia subjects (SZ) from the left and right hemisphere.
GluN2B was identified as a single band at the expected molecular
weight (175 kDa). c. [3H] Ifenprodil binding to GluN2B revealed no
significant differences between schizophrenia (SZ) and control (CT)
subjects, in the left or right hemisphere. Bars represent mean + SEM.
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binding assay. Therefore, it is unlikely that the discrepancy
between binding and protein is a result of [3H] Ifenprodil
binding to non-GluN2B sites. It is possible however that
that these two techniques label different populations of
GluN2B subunits. Under the conditions used in the
present study (i.e. the use of tissue sections rather than
cell lysed homogenates), [3H] ifenprodil would bind pri-
marily to cell surface receptors, while the immunoblot
would detect GluN2B protein in all cellular compart-
ments. This suggests that the reduction observed in
GluN2B protein in the present study might represent a
reduction in intracellular protein levels. The implica-
tions of such localised reductions remain unclear [24].
Similar to our study, in cortical brain areas it has been
shown that despite no change in [3H] ifenprodil binding
[25], there was a reduction in GluN2B protein in schizo-
phrenia compared to control subjects, which was spe-
cific to the endoplasmic reticulum [26], suggesting there
may be altered production, degradation or trafficking of
GluN2B protein in schizophrenia. While we did not
examine GluN2B mRNA in the present study, two pre-
vious studies reported no change in GluN2B mRNA
levels in the dentate gyrus in schizophrenia [10,12],
therefore it is unlikely the findings in the present study
represent changes in GluN2B production. It is possible
however that our findings reflect disturbances to GluN2B
trafficking, degradation, or other aspects of GluN2B regu-
lation. Further studies, specifically examining isolated cel-
lular compartments and proteins that regulate trafficking/
degradation of GluN2B, as well as assessments of GluN2B
phosphorylation and activation would be important to fur-
ther understand the GluN2B alterations in the hippocam-
pus in schizophrenia.
GluN2B containing NMDARs play a critical role in cog-
nitive functions, especially in the hippocampus (For re-
view see [27]). Selective reduction of GluN2B-containing
NMDARs in the hippocampus has been reported to pro-
duce cognitive deficits in rodents [15,28] as well as dis-
rupting underlying molecular processes such as LTP [15].
Specifically, the left hippocampus has previously been as-
sociated with verbal and visual memory performance in
schizophrenia subjects [29]. Therefore, a reduction in
NMDARs or altered composition of the NMDAR subunits
in hippocampal subregions, such as that found in the
present study, may be a contributing factor to the cogni-
tive deficits observed in these patients. Therapies aim-
ing to enhance GluN2B function or activity have been
shown to improve cognitive function in animal models
of ageing-induced cognitive impairment [30]. Similarly,
over-expression of GluN2B in transgenic mice results in
increased cognitive ability [31]. Along these lines, positive
allosteric modulation, selective for GluN2B-containing
NMDARs has been proposed as a novel therapeutic strat-
egy for the treatment of schizophrenia and cognitive dys-
function more generally [16,17]. Our finding therefore of
reduced GluN2B protein in the hippocampus, is likely to
contribute to the cognitive symptoms in schizophrenia
patients, and supports the idea that GluN2B positive
Table 2 Pearsons correlations for continuous variables influencing GluN2B binding and protein expression in the
hippocampus of all subjects, control subjects only and schizophrenia subjects only
Variable All subjects Control Schizophrenia
GluN2B GluN2B GluN2B GluN2B GluN2B GluN2B
Protein Binding Protein Binding Protein Binding
n 38 41 19 21 19 20
Age at death r 0.16 ‐0.309 0.207 -0.408 0.152 -0.212
p 0.338 0.049 0.395 0.067 0.534 0.369
Post-mortem interval r ‐0.318 0.054 ‐0.483 0.061 -0.116 0.030
p 0.051 0.738 0.036 0.794 0.636 0.901
pH r ‐0.386 0.068 ‐0.662 0.226 0.162 -0.255
p 0.017 0.671 0.002 0.324 0.506 0.278
Brain weight r 0.067 -0.029 0.028 0.152 0.023 -0.218
p 0.688 0.855 0.908 0.512 0.926 0.356
Duration of illness r N/A N/A N/A N/A -0.056 -0.192
p N/A N/A N/A N/A 0.819 0.430
Age of onset r N/A N/A N/A N/A 0.313 0.007
p N/A N/A N/A N/A 0.193 0.977
Estimated daily antipsychotic drug dose r N/A N/A N/A N/A -0.156 -0.368
p N/A N/A N/A N/A 0.525 0.111
Significant and borderline significant correlations are highlighted in bold. N/A, not applicable.
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allosteric modulators could potentially be therapeutic for
cognitive dysfunctions in schizophrenia.
As with all post-mortem human brain studies of this
nature, we cannot rule out an influence of ante-mortem
medication on our data. However, we observed no cor-
relation between antipsychotic dose (measured as chlor-
promazine equivalents) and GluN2B binding or protein
levels. Furthermore, there is evidence from animal studies
that antipsychotic drug treatment does not alter GluN2B
protein levels in the brain [32-34], suggesting that our find-
ings are unlikely to be due to the effects of pre-mortem
antipsychotic drug treatment.
Conclusion
In conclusion, the present study for the first time revealed
that GluN2B protein levels are significantly decreased
specifically in the left hippocampus (dentate gyrus) of
schizophrenia subjects compared to controls. We suggest
this reduction may be associated with cognitive symptoms
arising in schizophrenia subjects. While further studies are
warranted to determine the functional implications of this
reduction and if this reduction is common to other GluN2
subunits or hippocampal subregions, our findings provide
preliminary support for the development of GluN2B se-
lective positive modulators as a novel therapy for schizo-
phrenia, especially the cognitive dysfunctions.
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